N-Acetylcysteine Alleviates the Progression of Chronic Kidney Disease: A Three-Year Cohort Study
- PMID: 38004033
- PMCID: PMC10673586
- DOI: 10.3390/medicina59111983
N-Acetylcysteine Alleviates the Progression of Chronic Kidney Disease: A Three-Year Cohort Study
Abstract
Background and Objectives: The prevalence of chronic kidney disease (CKD) is approximately 10% of the population in many countries. CKD progresses to end-stage renal disease (ESRD), resulting in adverse outcomes, prolonged hospitalization, and increased healthcare costs. Therefore, reducing CKD progression to ESRD is recognized as an important health issue. Materials and Methods: Data from the study participants with stage 3 to stage 5 CKD (n = 7668) were collected from the National Health Insurance (NHI) program in Taiwan (1 November 2014 to 31 December 2020). CKD patients who had ingested or not ingested N-acetylcysteine (NAC) for three years were divided into the study group (NAC users; n = 165) and the control group (NAC non-users; n = 165) to explore whether NAC use could alleviate CKD progression and reduce the risks associated with hemodialysis in CKD patients. Results: The levels of serum creatinine (SCr) and estimated globular filtration rate (eGFR) were nearly unchanged and/or slightly changed in NAC users, but the SCr levels were slightly increased, and the eGFR levels were significantly decreased in NAC non-users at the six-month interval during the three years. A statistical difference was observed between the two groups for both levels from 12 months to 36 months. The incidence rate of hemodialysis was significantly lower in NAC users than in non-NAC users (4.8% vs. 12.7%, Wald test = 5.947, p = 0.015, OR = 34.9). These results indicated that NAC use may improve renal function of CKD patients by modulating SCr and eGFR and, in turn, reducing the risk of hemodialysis. Conclusions: We investigated whether NAC could be used to reduce CKD progression to ESRD. For the three-year retrospective study, the incidence rate of hemodialysis was significantly lower in NAC users than in non-NAC users via modulating SCr and eGRF levels. NAC use might be a useful clinical approach for reducing CKD progression to ESRD.
Keywords: N-acetylcysteine; chronic kidney disease; end-stage renal disease.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Protective effect of N-acetylcysteine on progression to end-stage renal disease: Necessity for prospective clinical trial.Eur J Intern Med. 2017 Oct;44:67-73. doi: 10.1016/j.ejim.2017.06.011. Epub 2017 Jun 17. Eur J Intern Med. 2017. PMID: 28633804
-
Association between Monocyte Count and Risk of Incident CKD and Progression to ESRD.Clin J Am Soc Nephrol. 2017 Apr 3;12(4):603-613. doi: 10.2215/CJN.09710916. Epub 2017 Mar 27. Clin J Am Soc Nephrol. 2017. PMID: 28348030 Free PMC article.
-
Treatment for non-thyroidal illness syndrome in advanced chronic kidney disease: a single-blind controlled study.J Nephrol. 2017 Aug;30(4):557-565. doi: 10.1007/s40620-016-0341-2. Epub 2016 Aug 2. J Nephrol. 2017. PMID: 27485006 Clinical Trial.
-
Drug therapies to delay the progression of chronic kidney disease.Clin Med (Lond). 2015 Dec;15(6):550-7. doi: 10.7861/clinmedicine.15-6-550. Clin Med (Lond). 2015. PMID: 26621944 Free PMC article. Review.
-
N-acetylcysteine in Kidney Disease: Molecular Mechanisms, Pharmacokinetics, and Clinical Effectiveness.Kidney Int Rep. 2024 Jul 20;9(10):2883-2903. doi: 10.1016/j.ekir.2024.07.020. eCollection 2024 Oct. Kidney Int Rep. 2024. PMID: 39430194 Free PMC article. Review.
Cited by
-
N-acetyl-L-cysteine improves mitochondrial and oxidative defects in the acadian variant of fanconi syndrome.Exp Biol Med (Maywood). 2025 May 23;250:10448. doi: 10.3389/ebm.2025.10448. eCollection 2025. Exp Biol Med (Maywood). 2025. PMID: 40488120 Free PMC article.
-
Effect of N-acetylcysteine on antimicrobials induced nephrotoxicity: a meta-analysis.BMC Nephrol. 2025 Mar 8;26(1):128. doi: 10.1186/s12882-025-04037-y. BMC Nephrol. 2025. PMID: 40057704 Free PMC article.
-
Antioxidants and Reactive Oxygen Species: Shaping Human Health and Disease Outcomes.Int J Mol Sci. 2025 Aug 4;26(15):7520. doi: 10.3390/ijms26157520. Int J Mol Sci. 2025. PMID: 40806653 Free PMC article. Review.
-
The Clinical Utility and Plausibility of Oxidative and Antioxidant Variables in Chronic and End-Stage Kidney Disease: A Review of the Literature.Int J Mol Sci. 2025 Apr 4;26(7):3376. doi: 10.3390/ijms26073376. Int J Mol Sci. 2025. PMID: 40244241 Free PMC article. Review.
References
-
- Wen C.P., Cheng T.Y., Tsai M.K., Chang Y.C., Chan H.T., Tsai S.P., Chiang P.H., Hsu C.C., Sung P.K., Hsu Y.H., et al. All-cause mortality attributable to chronic kidney disease: A prospective cohort study based on 462 293 adults in Taiwan. Lancet. 2008;371:2173–2182. doi: 10.1016/S0140-6736(08)60952-6. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous